Boston, Massachusetts | April 13, 2026
Vivatides Therapeutics has announced the successful completion of a $54 million oversubscribed Series A financing round, marking a significant milestone in advancing next-generation RNA therapeutics beyond liver-targeted delivery. The funding round, led by Qiming Venture Partners with participation from multiple healthcare-focused investors, reflects growing confidence in the company’s innovative extrahepatic RNA delivery platform. This capital infusion will support the expansion of Vivatides’ preclinical pipeline, platform optimization, and transition toward clinical development, positioning the company at the forefront of a rapidly evolving RNA medicine landscape.
Series A Funding Accelerates RNA Platform Development
The $54 million Series A financing will enable Vivatides to accelerate the development of its proprietary platform designed to deliver RNA-based therapeutics such as siRNA and antisense oligonucleotides (ASOs) to tissues beyond the liver. This represents a major advancement, as most existing RNA therapies are limited to hepatic delivery due to biological and technological constraints.
By overcoming this limitation, Vivatides aims to unlock new therapeutic possibilities across a broad range of diseases, including oncology, cardiovascular disorders, and chronic conditions. The strong investor participation and oversubscription highlight the high market potential and scientific promise of expanding RNA therapeutics into previously inaccessible tissues.
Innovative Extrahepatic Delivery Unlocks New Treatment Possibilities
Advertisement
At the core of Vivatides’ technology is a novel ligand conjugation approach, enabling targeted and precise delivery of RNA molecules to non-liver tissues. This platform enhances tissue specificity while minimizing off-target effects, addressing one of the most critical challenges in RNA medicine.
Preclinical studies have demonstrated improved delivery efficiency and favorable safety profiles, supporting the platform’s potential for clinical translation. The ability to deliver RNA therapies beyond the liver could significantly expand the applicability of gene-silencing and gene-modulation technologies, paving the way for breakthrough treatments in diseases that have remained difficult to target with existing RNA-based approaches.
Strong Scientific Leadership and Pipeline Expansion Strategy
Vivatides is supported by a leadership team with extensive experience in RNA therapeutics and drug development, providing a strong foundation for advancing its platform into clinical trials. The company is leveraging its expertise in sequence design, delivery optimization, and translational research to build a diversified pipeline of RNA-based therapies.
The new funding will also support the development of multiple therapeutic candidates, each designed to address high unmet medical needs. As the company progresses toward clinical validation, its integrated approach to platform innovation and pipeline development is expected to play a critical role in shaping the future of RNA medicine.
Growing Investor Confidence in Next-Generation RNA Therapies
The successful funding round reflects broader industry trends, with increasing investment in next-generation therapeutic platforms that address limitations of current technologies. RNA therapeutics have gained significant momentum following recent breakthroughs, but challenges in delivery have restricted their full potential. Vivatides’ approach directly addresses this gap, positioning the company as a key innovator in the field. The strong investor interest underscores the belief that expanding RNA delivery capabilities could transform treatment paradigms and unlock new markets in precision medicine.
The $54 million Series A financing marks a pivotal step for Vivatides Therapeutics as it advances its mission to expand the reach of RNA-based therapies beyond traditional limitations. With a robust platform, strong scientific leadership, and growing investor support, the company is well-positioned to drive innovation in precision medicine and next-generation therapeutics. If successful, Vivatides’ technology could redefine the boundaries of RNA medicine, enabling new treatment options for a wide range of previously untreatable diseases and accelerating the evolution of modern biotechnology.
Source: Vivatides Therapeutics press release
